![](https://nordiclifescience.org/wp-content/uploads/2016/04/money-sek-e1461062629960.jpg)
Acquisition - April 19, 2016
Xvivo makes recommended public bid for Vivoline
The Swedish company Xvivo Perfusion has made a recommended public offer to holders of shares in Vivoline Medical. The company offers for every share in Vivoline 1.2921 Swedish crown in cash and 0.1543 shares in Xvivo Perfusion. The consideration corresponds to a value of about 9.32 Swedish crowns per share. The company says the total value of […]
![](https://nordiclifescience.org/wp-content/uploads/2014/10/agreement.jpg)
MedTech Business - January 1, 2016
XVIVO has been granted CE mark
XVIVO Perfusion has been granted a CE mark for a patent-protected product, PrimECC®, developed to prime the heart-lung machine before open heart surgery. The company will expand the clinical documentation for PrimECC® through additional clinical studies in 2016. PrimECC® is a fluid developed in collaboration with Professor Stig Steen in Lund to prime heart-lung machines […]